APO RESEARCH · REPORT
Immuno-Oncology
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
Product & engineering
Understand the product.
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
Selected research
Industry Growth & Trends
Global Immuno-Oncology Industry Growth and Trends Forecast to 2032
Market perspective
Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
According to APO Research, the global Immuno-Oncology market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
Report Scope
Read the full market overview
This report provides a structured, data-driven view of the global Immuno-Oncology market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Immuno-Oncology market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Immuno-Oncology market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Immuno-Oncology.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Immuno-Oncology market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Immuno-Oncology Market by Company
Bristol-Myers Squibb
Merck & Co., Inc.
Roche AG
AstraZeneca, Plc
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Immuno-Oncology Segment by Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Others
Immuno-Oncology Segment by Application
Hospitals
Drugstores
Others
Immuno-Oncology Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-Oncology market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Immuno-Oncology and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-Oncology.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Immuno-Oncology companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Immune Checkpoint Inhibitors
- Cytokine-Based Immunotherapy
- Cancer Vaccines
- CAR-T Cell Therapy
- Others
Applications
- Hospitals
- Drugstores
- Others
Companies covered
- Bristol-Myers Squibb
- Merck & Co., Inc.
- Roche AG
- AstraZeneca, Plc
- Sanofi S.A.
- Dendreon Pharmaceuticals
- Novartis
- Gilead Sciences Inc.
- Merck KGaA
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Immuno-Oncology Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Immuno-Oncology Market Size by Region (2021-2032)
- 1.4.1 Global Immuno-Oncology Market Size by Region (2021-2026)
- 1.4.2 Global Immuno-Oncology Market Size by Region (2027-2032)
- 1.5 Key Regions Immuno-Oncology Market Size (2021-2032)
- 1.5.1 North America Immuno-Oncology Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Immuno-Oncology Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Immuno-Oncology Market Size Growth Rate (2021-2032)
- 1.5.4 South America Immuno-Oncology Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Immuno-Oncology Market Size Growth Rate (2021-2032)
2 Immuno-Oncology Market by Type
- 2.1 Type Introduction
- 2.1.1 Immune Checkpoint Inhibitors
- 2.1.2 Cytokine-Based Immunotherapy
- 2.1.3 Cancer Vaccines
- 2.1.4 CAR-T Cell Therapy
- 2.1.5 Others
- 2.2 Global Immuno-Oncology Market Size by Type
- 2.2.1 Global Immuno-Oncology Market Size Overview by Type (2021-2032)
- 2.2.2 Global Immuno-Oncology Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Immuno-Oncology Market Size Forecasted by Type (2027-2032)
- 2.3 Global Immuno-Oncology Market Size by Regions
- 2.3.1 North America Immuno-Oncology Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Immuno-Oncology Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Immuno-Oncology Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Immuno-Oncology Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Immuno-Oncology Market Size Breakdown by Type (2021-2026)
3 Immuno-Oncology Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospitals
- 3.1.2 Drugstores
- 3.1.3 Others
- 3.2 Global Immuno-Oncology Market Size by Application
- 3.2.1 Global Immuno-Oncology Market Size Overview by Application (2021-2032)
- 3.2.2 Global Immuno-Oncology Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Immuno-Oncology Market Size Forecasted by Application (2027-2032)
- 3.3 Global Immuno-Oncology Market Size by Regions
- 3.3.1 North America Immuno-Oncology Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Immuno-Oncology Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Immuno-Oncology Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Immuno-Oncology Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Immuno-Oncology Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Immuno-Oncology Industry Trends
- 4.2 Immuno-Oncology Industry Drivers
- 4.3 Immuno-Oncology Industry Opportunities and Challenges
- 4.4 Immuno-Oncology Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Immuno-Oncology Revenue (2021-2026)
- 5.2 Global Immuno-Oncology Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Immuno-Oncology Key Company Headquarters & Area Served
- 5.4 Global Immuno-Oncology Company, Product Type & Application
- 5.5 Global Immuno-Oncology Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Immuno-Oncology Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Immuno-Oncology Players Market Share by Revenue in 2025
- 5.6.3 2025 Immuno-Oncology Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Bristol-Myers Squibb
- 6.1.1 Bristol-Myers Squibb Company Information
- 6.1.2 Bristol-Myers Squibb Business Overview
- 6.1.3 Bristol-Myers Squibb Immuno-Oncology Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Bristol-Myers Squibb Immuno-Oncology Product Portfolio
- 6.1.5 Bristol-Myers Squibb Recent Developments
- 6.2 Merck & Co., Inc.
- 6.2.1 Merck & Co., Inc. Company Information
- 6.2.2 Merck & Co., Inc. Business Overview
- 6.2.3 Merck & Co., Inc. Immuno-Oncology Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Merck & Co., Inc. Immuno-Oncology Product Portfolio
- 6.2.5 Merck & Co., Inc. Recent Developments
- 6.3 Roche AG
- 6.3.1 Roche AG Company Information
- 6.3.2 Roche AG Business Overview
- 6.3.3 Roche AG Immuno-Oncology Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Roche AG Immuno-Oncology Product Portfolio
- 6.3.5 Roche AG Recent Developments
- 6.4 AstraZeneca, Plc
- 6.4.1 AstraZeneca, Plc Company Information
- 6.4.2 AstraZeneca, Plc Business Overview
- 6.4.3 AstraZeneca, Plc Immuno-Oncology Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 AstraZeneca, Plc Immuno-Oncology Product Portfolio
- 6.4.5 AstraZeneca, Plc Recent Developments
- 6.5 Sanofi S.A.
- 6.5.1 Sanofi S.A. Company Information
- 6.5.2 Sanofi S.A. Business Overview
- 6.5.3 Sanofi S.A. Immuno-Oncology Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Sanofi S.A. Immuno-Oncology Product Portfolio
- 6.5.5 Sanofi S.A. Recent Developments
- 6.6 Dendreon Pharmaceuticals
- 6.6.1 Dendreon Pharmaceuticals Company Information
- 6.6.2 Dendreon Pharmaceuticals Business Overview
- 6.6.3 Dendreon Pharmaceuticals Immuno-Oncology Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Dendreon Pharmaceuticals Immuno-Oncology Product Portfolio
- 6.6.5 Dendreon Pharmaceuticals Recent Developments
- 6.7 Novartis
- 6.7.1 Novartis Company Information
- 6.7.2 Novartis Business Overview
- 6.7.3 Novartis Immuno-Oncology Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Novartis Immuno-Oncology Product Portfolio
- 6.7.5 Novartis Recent Developments
- 6.8 Gilead Sciences Inc.
- 6.8.1 Gilead Sciences Inc. Company Information
- 6.8.2 Gilead Sciences Inc. Business Overview
- 6.8.3 Gilead Sciences Inc. Immuno-Oncology Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Gilead Sciences Inc. Immuno-Oncology Product Portfolio
- 6.8.5 Gilead Sciences Inc. Recent Developments
- 6.9 Merck KGaA
- 6.9.1 Merck KGaA Company Information
- 6.9.2 Merck KGaA Business Overview
- 6.9.3 Merck KGaA Immuno-Oncology Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Merck KGaA Immuno-Oncology Product Portfolio
- 6.9.5 Merck KGaA Recent Developments
7 North America
- 7.1 North America Immuno-Oncology Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Immuno-Oncology Market Size by Country (2021-2026)
- 7.3 North America Immuno-Oncology Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Immuno-Oncology Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Immuno-Oncology Market Size by Country (2021-2026)
- 8.3 Europe Immuno-Oncology Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Immuno-Oncology Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Immuno-Oncology Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Immuno-Oncology Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Immuno-Oncology Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Immuno-Oncology Market Size by Country (2021-2026)
- 10.3 South America Immuno-Oncology Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Immuno-Oncology Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Immuno-Oncology Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Immuno-Oncology Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst